Stock Scorer

Eloxx Pharmaceuticals, Inc. (ELOX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 70K 140K 210K Q4 '11: 200K Q1 '12: 0 Q2 '12: 0 Q3 '12: 0 Q4 '12: 0 Q4 '11 Q1 '12 Q2 '12 Q3 '12 Q4 '12

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '20: -13.8M Q2 '20: -7.6M Q3 '20: -6.3M Q4 '20: -5.8M Q1 '21: -8.4M Q2 '21: -35.7M Q3 '21: -10.2M Q4 '21: -11.6M Q1 '22: -11M Q2 '22: -10.3M Q3 '22: -7.1M Q4 '22: -6M Q1 '23: -5.5M Q2 '23: -4.1M Q3 '23: -3.6M Q4 '23: -4M Q1 '25: -1.2M Q2 '25: -1.6M Q1 '26: -3.8M Q2 '26: -4.5M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '20: -13.9M Q2 '20: -7.9M Q3 '20: -6.6M Q4 '20: -6.1M Q1 '21: -8.7M Q2 '21: -36.1M Q3 '21: -9.9M Q4 '21: -12.1M Q1 '22: -11.6M Q2 '22: -10.6M Q3 '22: -7.5M Q4 '22: -6.3M Q1 '23: -6.2M Q2 '23: -4.3M Q3 '23: -3.6M Q4 '23: -2.9M Q1 '25: -1.7M Q2 '25: -1.9M Q1 '26: -3.8M Q2 '26: -4.5M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-15M -10M -5M 0 5M 10M 15M Q1 '20: -11.9M Q2 '20: -6.3M Q3 '20: -5.3M Q4 '20: -4.7M Q1 '21: -7.7M Q2 '21: -9.8M Q3 '21: -7.6M Q4 '21: -9.9M Q1 '22: -9.5M Q2 '22: -9.7M Q3 '22: -6.9M Q4 '22: -5.7M Q1 '23: -6.8M Q2 '23: -2.1M Q3 '23: -3.5M Q4 '23: -2M Q1 '25: 1.2M Q2 '25: -1.8M Q1 '26: -5.5M Q2 '26: -4.8M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-12M -8M -4M 0 4M 8M 12M Q1 '17: -2.8M Q2 '17: -3.2M Q3 '17: -634.3K Q4 '17: 6.2M Q1 '18: -5.8M Q2 '18: -8.6M Q3 '18: -8.1M Q4 '18: -9.2M Q1 '19: -9.2M Q2 '19: -9.6M Q3 '19: -11.3M Q4 '19: -9.3M Q4 '21: -10M Q1 '22: -9.5M Q2 '22: -9.8M Q3 '22: -7M Q4 '22: -5.7M Q1 '23: -6.8M Q2 '23: -2.1M Q3 '23: -3.5M Q2 '17 Q1 '18 Q4 '18 Q3 '19 Q1 '22 Q4 '22 Q3 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '21: 66.4M Q3 '21: 86.2M Q1 '22: 2.2M Q2 '22: 2.2M Q3 '22: 2.2M Q1 '23: 2.2M Q2 '23: 2.2M Q3 '23: 2.7M Q1 '25: 3.8M Q2 '25: 347K Q1 '26: 48.2M Q2 '26: 6.8M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q1 '19: -1.47 Q2 '19: -1.45 Q3 '19: -1.45 Q4 '19: -1.34 Q1 '20: -1.36 Q2 '20: -1.16 Q3 '20: -1.00 Q4 '20: -0.86 Q1 '21: -0.73 Q2 '21: -1.07 Q3 '21: -1.02 Q4 '21: -38.17 Q1 '22: -43.31 Q2 '22: -47.67 Q3 '22: -51.03 Q4 '22: -16.65 Q1 '23: -14.17 Q2 '23: -11.23 Q3 '23: -9.07 Q4 '23: -6.82 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for ELOX: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.